Participated · Seed · Mar 2026

Ternary Therapeutics combines physics-informed artificial intelligence with rapid experimental validation to design molecular glue therapeutics that bring proteins together to target diseases considered previously undruggable. The company is advancing a pipeline of programs aimed at inflammatory and neuroinflammatory diseases and plans to use recently raised seed capital to scale its platform and progress programs toward preclinical development. The €4.1 million seed round was led by daphni with participation from Pace Ventures, the i&i Biotech Fund, and UKI2S (managed by Future Planet Capital). Ternary has also strengthened its leadership by appointing Dr. Ian Taylor to its board, drawing on his experience in targeted protein degradation. The company is based in London and intends to grow its team and capabilities as part of its next phase of development.

Participated · Series A · Mar 2026

Antiverse combines proprietary generative machine-learning models with programmable cell-line engineering to rapidly create epitope-specific, therapeutic-grade antibodies against difficult targets such as GPCRs and ion channels. Its lab-in-the-loop workflow reportedly reduces de novo antibody development timelines to under four months, integrating in-silico design with in-house build and validation. The company supports partnered discovery programs with several top-20 pharmaceutical firms and has just launched a research collaboration with the Cystic Fibrosis Foundation to generate antibodies targeting the extracellular region of CFTR. Backed by more than $20 million in total funding, Antiverse is expanding its platform, accelerating its internal pipeline, and intends to move its first wholly owned candidates into later-stage preclinical development by 2027. Headquartered in Cardiff, UK, with offices in Boston and Prague, the team has spent seven years training its models on challenging targets to optimize physicochemical properties and humanness of antibodies. Antiverse offers flexible collaboration structures to biotechnology, pharmaceutical, and foundation partners while simultaneously advancing its own therapeutics.

Participated · Series A · Dec 2025

T-Curx is a spin-out from the University Clinics Würzburg that is building a pipeline of next-generation CAR-T cell therapies produced with virus-free, Sleeping-Beauty transposon gene-transfer technology. The platform is designed to enable scalable, cost-effective manufacturing and to open the door to in-vivo CAR-T generation. The company is initially advancing clinical candidates for acute myeloid leukemia (AML) and solid tumor indications. Proceeds from its recent Series A financing will accelerate these clinical programs and further develop the proprietary non-viral technologies. Led by CEO Ulf Grawunder, PhD, and Prof. Michael Hudecek, T-Curx aims to deliver more accessible and effective cell-based cancer treatments. The $20 million raise marks the company’s first institutional round, providing runway for near-term clinical milestones.

Participated · Equity · Nov 2025

Captain T Cell is a biotech spin-off from the Max Delbrück Center for Molecular Medicine that is building a pipeline of tumour-targeting TCR-T cell therapies. Its lead autologous candidate, CTC127, targets the MAGE-A4 antigen and will enter the TOMATA Phase I trial across nine German cancer centres, addressing lung, bladder, gastro-oesophageal, ovarian, and head-and-neck cancers. The company’s engineering “toolbox” adds functional armouring to T cells to enhance anti-tumour activity, persistence, and resilience within the solid-tumour microenvironment. In parallel, Captain T Cell is advancing a first-in-class allogeneic “off-the-shelf” TCR-T platform that has shown complete tumour responses in pre-clinical in-vivo studies. Management also plans to extend the toolbox toward in-vivo T-cell therapy applications. With the newly secured capital, the TOMATA trial is fully funded and the allogeneic program is positioned for clinical readiness, giving the firm multiple upcoming value-inflection points. Including earlier grants, Captain T Cell now has €20 million of available funding to execute its near-term clinical plans.

Led · Series A · Nov 2023

HeartBeat.bio is a Vienna-based biotech developing a human organoid cultivation, screening and AI-supported data analysis solution for cardiac drug development. Its cardioid drug discovery platform relies on self-assembling, highly reproducible cardiac organoids that recapitulate human physiology and enable modeling of heart diseases not achieved with other in-vitro systems. The company is currently focused on drug-induced and various subtypes of genetic cardiomyopathies, with additional programs planned in diabetic cardiomyopathy, myocardial infarction and cardiac remodeling/fibrosis. Led by CEO Michael Krebs, HeartBeat.bio intends to use the funds to complete its cardioid platform for proprietary and collaborative drug discovery programs. Financially, the company closed a €4.5M Pre-Series A round. The platform combines organoid biology and AI-enabled data analysis to accelerate development of therapeutics for heart failure and related indications. HeartBeat.bio is a Vienna, Austria-based spin-off of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) developing a high-throughput 3D screening platform for heart diseases using self-organizing human cardiac organoids called Cardioids. The Cardioid technology, invented by the Mendjan lab at IMBA, enables automated, reproducible, and cost-effective large-scale generation and analysis of cardiac organoids suitable for high-throughput compound screening. The company intends to use the €1.5m seed financing to establish operations, build an experienced team over the next 12 months, and develop Cardioid into a platform solution for compound screening. Its drug discovery program will focus on heart failure, cardiomyopathies, and cardiotoxicity studies for new drug candidates. HeartBeat.bio has signed an exclusive license and collaboration agreement with IMBA and will closely cooperate with Sasha Mendjan's research group to further develop the technology. The company has also received financial support from AWS via the AWS Pre-Seed Program and from Vienna's INiTS AplusB Scaleup Program.